Wednesday, February 28, 2018 7:06:12 PM
In the back of my mind, I am hoping that they announce lipid phase two topline results First, and then decide which drug gets them a better partner deal, and take it. They could then go one drug alone, with a ton of cash. If they didn’t immediately partner after 5211 and the nash data was good, it would make them much more likely to be a realistic buyout target, adding in a 5211 partner muddies a buyout situation, which I really think is the ultimate goal.
Nash drugs are dropping like flies. But The statin making companies would drop like flies if our nash drug is half as good as the phase 1 lipid lowering data looked like, barring unforeseen side effects of course. But hey, we are so close to data now. You always worry in early or mid trial that a drug trial will get halted if strange stuff happens medically. But we are like at the finish line. Odds of some awful side effect emerging become a little less imho, the longer the trial is allowed to continue. so I *expect (imho) to see nothing awful as we wait for these final patients to finish the primary endpoint stuff. They are constantly enrolling and so people finish the trial in piecemeal fashion. Kinda like various groups of runners starting a marathon at staggered times.
Statin making companies have a lot of cash after all these years of people being stuck on statins. Statins aren’t necessarily viewed as the fix-all that they once were thought to be, they are sometimes hard on the muscles and liver in certain cases and make some people feel like crap (imho). Used to be that anyone with any kind of cardiac anything going on, hand them a statin.
Easier to buy VKTX out than MDGL, especially if 5211 could be utilized in any fashion by the buyer.
It’s still just wishful thinking, but I have high hopes that our nash data will Continue to show the large magnitude of effect it showed in phase 1’s. If phase 2 nash is even close to phase 1, this thing might go to the moon. If our lipid lowering effects are better than MDGL, the value gap may finally close, once and for all.
I’m just hoping that they don’t make us wait on the lipid data. 1H18 better mean 1H18 :) I’m a patient man, but come on, throw us a bone here and hit a home run in a timely manner haha.
I’m just as excited as I was in the beginning, no matter how fast our price has moved in the direction of a fair valuation... hoping they give us a few breadcrumbs at the conference call coming up.
Take care brother, best wishes to the rest
Recent VKTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/21/2024 01:20:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 08:29:51 PM
- Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 11:23:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 12:13:31 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:05:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:56:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 09:55:09 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/24/2024 09:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:10:08 PM
- Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 07/24/2024 08:05:00 PM
- US Index Futures Fall Amid Tech Giant Earnings, Oil Prices Rise • IH Market News • 07/24/2024 09:55:54 AM
- Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:05:00 PM
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association • PR Newswire (US) • 06/24/2024 11:33:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:10:11 AM
- Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) • PR Newswire (US) • 06/04/2024 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 08:03:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/22/2024 09:12:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/22/2024 08:33:26 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM